Cancer Patient Shares mRNA Vaccine Trial Experience
A clinical trial participant discusses his successful treatment for high-risk melanoma using an mRNA vaccine.
Updated on Oct. 15, 2026 in Cancer
Schoolteacher Gary Keblish shared his experience participating in a clinical trial for an mRNA cancer vaccine at the recent STAT Summit. Keblish, who was diagnosed with high-risk melanoma in 2019, received a combination therapy involving the vaccine and Keytruda.
Why it matters
The clinical trial for this mRNA vaccine, developed by Merck and Moderna, represents a significant development in personalized cancer immunotherapy. Understanding patient experiences in such trials provides critical insight into the efficacy and side effects of emerging medical treatments.
Gary Keblish remains tumor-free six years after the removal of his high-risk melanoma. His treatment regimen combined the immunotherapy drug Keytruda with an mRNA cancer vaccine developed by Merck and Moderna.
The players
Gary Keblish
He is a schoolteacher who participated in a clinical trial for an mRNA melanoma vaccine.
Jeffrey Weber
He serves as the deputy director of the Perlmutter Cancer Center at NYU Langone.
Merck
This global pharmaceutical company co-developed the mRNA cancer vaccine used in the trial.
Moderna
This biotechnology company specializes in mRNA-based therapies and co-developed the cancer vaccine.
The details
Participants in the trial were selected through a drawing process to receive the joint vaccine and Keytruda treatment. While undergoing the regimen, Keblish experienced neuropathy as a side effect, though he has continued to work as a schoolteacher throughout his recovery.
Timeline
2019: Gary Keblish received a high-risk melanoma diagnosis.
August 2026: Merck and Moderna announced clinical trial results.
October 15, 2026: Gary Keblish spoke about his treatment experience at the STAT Summit.
The Big Picture
This report follows the development of the mRNA cancer vaccine clinical trial program. It extends the research findings of this initiative by highlighting successful long-term patient outcomes.
The clinical trial results offer potential new treatment pathways for patients diagnosed with high-risk melanoma. Patients should consult their oncologists regarding the availability of future mRNA-based immunotherapy trials.
The takeaway
The successful six-year outcome for this patient highlights the potential for mRNA technology to change cancer treatment protocols. Patients interested in emerging therapies should monitor clinical trial registries for upcoming research opportunities.
Further reading
For more information on the latest developments in oncology, visit the United States Cancer section.
